Deep learning-based multimodal model for predicting on-treatment histological outcomes in chronic hepatitis B-associated advanced liver fibrosis

Figure 3 Model performance. A and B: Performance of different model (purple for clinical-based, orange for hematoxylin and eosin-based, green for Masson-based, yellow for hematoxylin and eosin and Masson-based, blue for multimodal model) in the validation and test sets; C and D: Confusion matrix of the fusion model in the validation and test sets; E and F: Differences in model scores between the reversal and non-reversal groups in the validation and test sets. ^dP < 0.0001. ROC: Receiver operating characteristic; HE: Hematoxylin and eosin; AUC: Area under the receiver operating characteristic curve.